Diese Seite wurde automatisch übersetzt und die Genauigkeit der Übersetzung wird nicht garantiert. Bitte wende dich an die englische Version für einen Quelltext.

Alzheimer's Disease Neuroimaging Initiative 4 (ADNI4)

23. September 2026 aktualisiert von: Paul S. Aisen, University of Southern California

Alzheimer's Disease Neuroimaging Initiative 4 (ADNI4)

The Alzheimer's Disease Neuroimaging Initiative 4 (ADNI4) is a non-randomized, longitudinal, natural history study designed to validate biomarkers, improve clinical trial design, and advance understanding of Alzheimer's disease across the full disease spectrum. Building on the success of ADNI1, ADNI-GO, ADNI2, and ADNI3, ADNI4 integrates clinical, cognitive, imaging, genetic, and fluid biomarker data to characterize disease progression and predict cognitive decline.

ADNI4 includes both in-clinic and remote cohorts and a small complementary sub-cohort, Together Exploring Aging Minds (TEAM-ADNI), which evaluates community-based recruitment and longitudinal data collection approaches.

Studienübersicht

Status

Anmeldung auf Einladung

Bedingungen

Intervention / Behandlung

Detaillierte Beschreibung

Since its launch in 2004, the Alzheimer's Disease Neuroimaging Initiative (ADNI) has been a landmark public-private partnership focused on developing and validating biomarkers for Alzheimer's disease (AD) and improving clinical trial design. ADNI4 continues the previously funded ADNI1, ADNI-GO, ADNI2, and ADNI3 studies and integrates clinical, cognitive, imaging, genetic, and biochemical biomarker data to characterize the full spectrum of Alzheimer's disease, from normal cognition through dementia.

The ADNI4 study is a multi-center, non-randomized, longitudinal, natural history, non-treatment study. Approximately 1,500 participants will be enrolled across three cohorts: cognitively normal (CN), mild cognitive impairment (MCI), and dementia (DEM). Participants between the ages of 55 and 90 years will be enrolled at sites across the United States and Canada. Approximately 750 participants will be newly enrolled into ADNI4, and approximately 750 participants will be rollover participants continuing from prior ADNI studies. Clinical, cognitive, imaging, biomarker, and genetic characteristics will be assessed longitudinally across the three cohorts.

Participants enrolled in ADNI4 will undergo longitudinal clinical and cognitive assessments, computerized cognitive batteries, biomarker and genetic testing, positron emission tomography (PET) imaging for amyloid and tau, magnetic resonance imaging (MRI), and collection of cerebrospinal fluid (CSF) for up to five years.

ADNI4 incorporates both in-clinic and remote approaches, including web-based cognitive assessments and blood-based biomarkers, to support scalable identification and longitudinal monitoring of individuals across the disease continuum and to inform future clinical trial design.

ADNI4 also includes the Together Exploring Aging Minds (TEAM-ADNI) cohort, a small complementary sub-cohort that evaluates community-based recruitment and flexible approaches to participant identification, enrollment, and longitudinal data collection.

Across cohorts, ADNI4 aims to validate imaging and fluid biomarkers, improve clinical trial design, characterize longitudinal cognitive and biomarker changes, and identify predictors of disease progression.

For more information, please visit the ADNI4 Study website: https://www.adni4.org/

Studientyp

Beobachtungs

Einschreibung (Geschätzt)

1500

Kontakte und Standorte

Dieser Abschnitt enthält die Kontaktdaten derjenigen, die die Studie durchführen, und Informationen darüber, wo diese Studie durchgeführt wird.

Studienorte

  • Kanada
    • British Columbia
      • Vancouver, British Columbia, Kanada, V6T 2B5
        • UBC Hospital Clinic for Alzheimer Disease and Related Disorders (CARD)
    • Ontario
      • London, Ontario, Kanada, N6C 0A7
        • Parkwood Institute
      • Toronto, Ontario, Kanada, M4N 3M5
        • Sunnybrook Health Sciences Centre
  • Vereinigte Staaten
    • Alabama
      • Birmingham, Alabama, Vereinigte Staaten, 35233
        • University of Alabama at Birmingham
    • Arizona
      • Phoenix, Arizona, Vereinigte Staaten, 85006
        • Banner Alzheimer's Institute
      • Phoenix, Arizona, Vereinigte Staaten, 85013
        • Barrow Neurological Institute
      • Sun City, Arizona, Vereinigte Staaten, 85351
        • Banner Sun Health Research Institute
    • California
      • Irvine, California, Vereinigte Staaten, 92697
        • University of California, Irvine
      • La Jolla, California, Vereinigte Staaten, 92037
        • University of California, San Diego
      • Los Angeles, California, Vereinigte Staaten, 90033
        • University of Southern California
      • Los Angeles, California, Vereinigte Staaten, 90024
        • University of California, Los Angeles
      • Palo Alto, California, Vereinigte Staaten, 94304
        • Stanford University
      • San Francisco, California, Vereinigte Staaten, 94158
        • University of California, San Francisco
      • Walnut Creek, California, Vereinigte Staaten, 94598
        • University of California, Davis
    • Connecticut
      • New Haven, Connecticut, Vereinigte Staaten, 06520
        • Yale University
    • District of Columbia
      • Washington D.C., District of Columbia, Vereinigte Staaten, 20060
        • Howard University
      • Washington D.C., District of Columbia, Vereinigte Staaten, 200072145
        • Georgetown University
    • Florida
      • Gainesville, Florida, Vereinigte Staaten, 32610
        • University of Florida
      • Jacksonville, Florida, Vereinigte Staaten, 32224
        • Mayo Clinic, Jacksonville
      • Miami, Florida, Vereinigte Staaten, 33135
        • Gonzalez MD & Aswad MD Health Services
      • Miami Beach, Florida, Vereinigte Staaten, 33140
        • Wien Center
      • Orlando, Florida, Vereinigte Staaten, 32803
        • Charter Research
      • Tampa, Florida, Vereinigte Staaten, 336134808
        • University of South Florida Health Byrd Alzheimer's Institute
    • Georgia
      • Atlanta, Georgia, Vereinigte Staaten, 30322
        • Emory University
    • Illinois
      • Chicago, Illinois, Vereinigte Staaten, 60611
        • Northwestern University
      • Chicago, Illinois, Vereinigte Staaten, 60637
        • University of Chicago
      • Chicago, Illinois, Vereinigte Staaten, 60654
        • AllianceChicago
      • Chicago, Illinois, Vereinigte Staaten, 60612
        • Rush University Memory Clinic
    • Indiana
      • Indianapolis, Indiana, Vereinigte Staaten, 46202
        • Indiana University
    • Iowa
      • Iowa City, Iowa, Vereinigte Staaten, 52242
        • University of Iowa
    • Kansas
      • Fairway, Kansas, Vereinigte Staaten, 66205
        • University of Kansas
    • Kentucky
      • Lexington, Kentucky, Vereinigte Staaten, 40536
        • University of Kentucky
    • Maryland
      • Baltimore, Maryland, Vereinigte Staaten, 21224
        • Johns Hopkins University
    • Massachusetts
      • Boston, Massachusetts, Vereinigte Staaten, 02118
        • Boston University
      • Boston, Massachusetts, Vereinigte Staaten, 02115
        • Beth Israel Deaconess Medical Center
      • Boston, Massachusetts, Vereinigte Staaten, 21155
        • Brigham and Women's Hospital
      • Boston, Massachusetts, Vereinigte Staaten, 02215
        • The Fenway Institute - Fenway Health
    • Michigan
      • Ann Arbor, Michigan, Vereinigte Staaten, 48109
        • University of Michigan, Ann Arbor
    • Minnesota
      • Rochester, Minnesota, Vereinigte Staaten, 55901
        • Mayo Clinic Alzheimer's Disease Research Center
    • Missouri
      • St Louis, Missouri, Vereinigte Staaten, 63108
        • Washington University, St Louis
    • Nevada
      • Las Vegas, Nevada, Vereinigte Staaten, 89101
        • Cleveland Clinic Lou Ruvo Center for Brain Health, Las Vegas
    • New York
      • Albany, New York, Vereinigte Staaten, 12208
        • Albany Medical College
      • Buffalo, New York, Vereinigte Staaten, 142261727
        • Dent Neurological Institute
      • New York, New York, Vereinigte Staaten, 10032
        • Columbia University Irving Medical Center
      • New York, New York, Vereinigte Staaten, 10016
        • New York University Langone Medical Center
      • New York, New York, Vereinigte Staaten, 100296552
        • Mount Sinai School of Medicine
      • New York, New York, Vereinigte Staaten, 10018
        • Clinical Directors Network, Inc
      • Orangeburg, New York, Vereinigte Staaten, 109621159
        • Nathan Kline Institute for Psychiatric Research
      • Rochester, New York, Vereinigte Staaten, 14620
        • University of Rochester
    • North Carolina
      • Durham, North Carolina, Vereinigte Staaten, 27705
        • Duke University Medical Center
      • Winston-Salem, North Carolina, Vereinigte Staaten, 27157
        • Wake Forest University Health Sciences
    • Ohio
      • Cleveland, Ohio, Vereinigte Staaten, 44122
        • Case Western Reserve University
      • Columbus, Ohio, Vereinigte Staaten, 43210
        • Ohio State University
    • Oklahoma
      • Tulsa, Oklahoma, Vereinigte Staaten, 74136
        • Central States Research
    • Oregon
      • Portland, Oregon, Vereinigte Staaten, 97239
        • Oregon Health & Science University
    • Pennsylvania
      • Philadelphia, Pennsylvania, Vereinigte Staaten, 19104
        • University of Pennsylvania
      • Pittsburgh, Pennsylvania, Vereinigte Staaten, 15213
        • University of Pittsburgh
    • Rhode Island
      • Providence, Rhode Island, Vereinigte Staaten, 02903
        • Rhode Island Hospital
      • Providence, Rhode Island, Vereinigte Staaten, 02906
        • Butler Hospital, Memory and Aging Program
    • South Carolina
      • Charleston, South Carolina, Vereinigte Staaten, 29401
        • Ralph H. Johnson VA Health Care System
    • Tennessee
      • Nashville, Tennessee, Vereinigte Staaten, 37212
        • Vanderbilt University Medical Center Center for Cognitive Medicine
    • Texas
      • Dallas, Texas, Vereinigte Staaten, 75390
        • University of Texas Southwestern Medical Center
      • Houston, Texas, Vereinigte Staaten, 77030
        • Baylor College of Medicine
      • San Antonio, Texas, Vereinigte Staaten, 78229
        • University of Texas Health Science Center at San Antonio
    • Wisconsin
      • Madison, Wisconsin, Vereinigte Staaten, 53792
        • University of Wisconsin

Teilnahmekriterien

Forscher suchen nach Personen, die einer bestimmten Beschreibung entsprechen, die als Auswahlkriterien bezeichnet werden. Einige Beispiele für diese Kriterien sind der allgemeine Gesundheitszustand einer Person oder frühere Behandlungen.

Zulassungskriterien

Studienberechtigtes Alter

55 Jahre bis 90 Jahre (Erwachsene, Älterer Erwachsener)

Akzeptiert gesunde Freiwillige

Ja

Studienberechtigte Geschlechter

Alle

Probenahmeverfahren

Wahrscheinlichkeitsstichprobe

Studienpopulation

Cognitively normal (CN), mild cognitive impairment (MCI), and dementia (DEM) participants.

Beschreibung

Inclusion Criteria for Newly Enrolled Participants, CN Cohort:

  1. Participant may or may not have a significant subjective memory concern as reported by participant, study partner, or clinician.

  2. Normal memory function documented by scoring above demographically-adjusted cutoffs on the Logical Memory II subscale (Delayed Paragraph Recall, Paragraph A only) from the Wechsler Memory Scale - Revised (the maximum score is 25):

    1. ≥9 for 16 or more years of education
    2. ≥ 5 for 8-15 years of education
    3. ≥ 3 for 0-7 years of education
    4. Note: cut-offs may be modified over time as the field evolves in this area

  3. Mini-Mental State Exam score between 24 and 30 (inclusive) (Exceptions may be made for participants with less than 8 years of education at the discretion of the Project Director and/or Clinical Core)

  4. Clinical Dementia Rating = 0. Memory Box score must be 0.

  5. Cognitively normal, based on an absence of significant impairment in cognitive functions or activities of daily living.

  6. Stability of Permitted Medications for 4 weeks. In particular, participants may:

    1. Take stable doses of antidepressants lacking significant anticholinergic side effects (if they are not currently depressed and do not have a history of major depression within the past 1 years)
    2. Estrogen replacement therapy is permissible
    3. Gingko biloba is permissible, but discouraged
    4. Washout from psychoactive medication (e.g., excluded antidepressants, neuroleptics, chronic anxiolytics or sedative hypnotics, etc.) for at least 4 weeks prior to screening.

Inclusion Criteria for Newly Enrolled Participants, MCI Cohort

  1. Participant must have a subjective memory concern as reported by participant, study partner, or clinician.

  2. Abnormal memory function documented by scoring within the demographically- adjusted ranges on the Logical Memory II subscale (Delayed Paragraph Recall, Paragraph A only) from the Wechsler Memory Scale - Revised (the maximum score is 25):

    1. ≤11 for 16 or more years of education
    2. ≤9 for 8-15 years of education
    3. ≤6 for 0-7 years of education.
    4. Note: cut-offs may be modified over time as the field evolves in this area.

  3. Mini-Mental State Exam score between 24 and 30 (inclusive) (Exceptions may be made for participants with less than 8 years of education at the discretion of the Project Director and/or Clinical Core)

  4. Clinical Dementia Rating = 0.5. Memory Box score must be at least 0.5

  5. General cognition and functional performance sufficiently preserved such that a diagnosis of dementia cannot be made by the site physician at the time of the screening visit.

  6. Stability of Permitted Medications for 4 weeks. In particular, participants may:

    1. Take stable doses of antidepressants lacking significant anticholinergic side effects (if they are not currently depressed and do not have a history of major depression within the past 1 year)
    2. Estrogen replacement therapy is permissible
    3. Gingko biloba is permissible, but discouraged
    4. Washout from psychoactive medication (e.g., excluded antidepressants, neuroleptics, chronic anxiolytics or sedative hypnotics, etc.) for at least 4 weeks prior to screening
    5. Cholinesterase inhibitors and memantine are allowable if stable for 12 weeks prior to screen
    6. Aducanumab and any other approved treatments for the neurobiology of AD if stable for 24 weeks prior to screen

Inclusion Criteria for Newly Enrolled Participants, DEM Cohort

  1. Participant must have a subjective memory concern as reported by participant, study partner, or clinician.

  2. Abnormal memory function documented by scoring within the demographically- adjusted ranges on the Logical Memory II subscale (Delayed Paragraph Recall, Paragraph A only) from the Wechsler Memory Scale - Revised (the maximum score is 25):

    1. ≤11 for 16 or more years of education
    2. ≤9 for 8-15 years of education
    3. ≤6 for 0-7 years of education.
    4. Note: cut-offs may be modified over time as the field evolves in this area.

  3. Mini-Mental State Exam score between 20 and 28 (inclusive) (Exceptions may be made for participants with less than 8 years of education at the discretion of the Project Director and/or Clinical Core)

  4. Clinical Dementia Rating = 0.5 or 1.0.

  5. Meets the National Institute on Aging/Alzheimer's Association Diagnostic Guidelines for Dementia (2011)

  6. Stability of Permitted Medications for 4 weeks. In particular, participants may:

    1. Take stable doses of antidepressants lacking significant anticholinergic side effects (if they are not currently depressed and do not have a history of major depression within the past 1 year)
    2. Estrogen replacement therapy is permissible
    3. Gingko biloba is permissible, but discouraged
    4. Washout from psychoactive medication (e.g., excluded antidepressants, neuroleptics, chronic anxiolytics or sedative hypnotics, etc.) for at least 4 weeks prior to screening
    5. Cholinesterase inhibitors and memantine are allowable if stable for 12 weeks prior to screen
    6. Aducanumab and any other approved treatments for the neurobiology of AD if stable for 24 weeks prior to screen

Inclusion Criteria for Newly Enrolled Participants, All Cohorts

  1. Geriatric Depression Scale score less than 10.
  2. Age between 55-90 years (inclusive).
  3. Study partner who has frequent contact with the participant (i.e., minimum average of 2 hours per week) and may be able to accompany the participant to clinic visits or provide information remotely (e.g. over the phone).
  4. Visual and auditory acuity adequate for neuropsychological testing.
  5. Good general health with no diseases expected to interfere with the study.
  6. Participant is not pregnant, lactating, or of childbearing potential (i.e., women must be two years post-menopausal or surgically sterile).
  7. Willing and able to participate in a longitudinal imaging study.
  8. Must be literate and speak English or Spanish fluently.
  9. Agrees to collection of blood for GWAS, APOE testing, DNA and RNA testing
  10. Agrees to collection of blood for biomarker testing.
  11. The Administrative Core, described in section 9.1.1, will collaborate with leadership from all Cores to review the blood biomarker data from the remote blood cohort and select participants to join the in-clinic cohort. See ADNI4: Remote protocol.
  12. Agrees to participate in the ADNI study which includes cognitive evaluation, MRI and PET scans.
  13. Flexibility can be made to all criteria for those with at least 8 years in a low socio-economic status (SES) neighborhood.

Inclusion Criteria for Rollover Participants, All Cohorts

The following additional inclusion criteria apply to all diagnostic categories for rollover participants only:

  1. Must have been enrolled and followed in one of the following previous ADNI studies: ADNIGO, ADNI2, ADNI3 for at least one year.
  2. Willing and able to continue to participant in an ongoing longitudinal study. A reduced battery of tests is allowable.
  3. Study partner may be available who has frequent contact with the participant (i.e., minimum average of 2 hours per week), and may be able to accompany the participant to clinic visits or provide information remotely (e.g. over the phone).

Exclusion Criteria for Newly Enrolled Participants, CN Cohort:

1.Any significant neurologic disease, such as Parkinson's disease, vascular cognitive impairment/dementia, Huntington's disease, normal pressure hydrocephalus, brain tumor, progressive supranuclear palsy, seizure disorder, subdural hematoma, multiple sclerosis, or history of significant head trauma followed by persistent neurologic defaults or known structural brain abnormalities

Exclusion Criteria for Newly Enrolled Participants, MCI and DEM Cohorts:

1.Any significant neurologic disease other than suspected Alzheimer's disease, such as Parkinson's disease (Parkinsonian symptoms complicating MCI/AD are acceptable), vascular cognitive impairment dementia (multiple lacunes less than or equal to 1.5 cm and/or extensive white matter changes are acceptable), Huntington's disease, normal pressure hydrocephalus, brain tumor (clinically insignificant meningioma acceptable), progressive supranuclear palsy, seizure disorder, subdural hematoma, multiple sclerosis, or history of significant head trauma followed by persistent neurologic defaults or known structural brain abnormalities.

Exclusion Criteria for Newly Enrolled Participants, All Cohorts:

Additional exclusion criteria apply to all diagnostic categories for newly enrolled participants:

  1. Screening/Baseline MRI brain scan with evidence of infection, or other clinically significant focal lesions. Participants with cortical strokes, not large enough to distort anatomy, multiple lacunar infarctions or extensive white matter disease are allowed.
  2. Screening/Baseline MRI brain scan with evidence of large structural abnormalities that would corrupt image analytical pipelines - e.g. large hemispheric infarcts, large areas of encephalomalacia, large arachnoid cysts
  3. Unable to complete MRIs for any reason (e.g. pacemaker or other implanted metal devices, severe claustrophobia, anxiety which prevents MRI scans, too large to fit, etc.).
  4. Current major depression, bipolar disorder as described in DMS-IV within the past 1 year. Psychotic features, agitation or behavioral problems within the last 3 months which could lead to difficulty complying with the protocol.
  5. Currently treated with medication for obsessive-compulsive disorder or attention deficit disorder.
  6. History of schizophrenia (DSM-5 criteria).
  7. History of alcohol or substance disorder within the past 2 years (DSM-5 criteria).
  8. Any significant systemic illness or unstable medical condition which could lead to difficulty complying with the protocol.
  9. Clinically significant abnormalities in B12, or thyroid function tests that might interfere with the study. A low B12 is exclusionary, unless follow-up labs (homocysteine (HC) and methylmalonic acid (MMA)) indicate that it is not physiologically significant.
  10. Residence in skilled nursing facility
  11. Current use of specific psychoactive medications (e.g. certain antidepressants, neuroleptics, chronic anxiolytics or sedative hypnotics, etc.), at the discretion of the clinician.
  12. Current use of any other exclusionary medications.
  13. Investigational agents are prohibited for five half-lives or one month, whichever time period is longer, prior to entry and for the duration of the trial.
  14. Participation in clinical studies involving neuropsychological measures being collected more than once time per year.
  15. Female that is pregnant, lactating, or of childbearing potential.
  16. Flexibility can be made to all criteria for those with at least 8 years in a low socio-economic status (SES) neighborhood.

Studienplan

Dieser Abschnitt enthält Einzelheiten zum Studienplan, einschließlich des Studiendesigns und der Messung der Studieninhalte.

Wie ist die Studie aufgebaut?

Designdetails

  • Beobachtungsmodelle: COHORT
  • Zeitperspektiven: PROSPECTIVE

Kohorten und Interventionen

Gruppe / Kohorte
Intervention / Behandlung
Cognitively Normal (CN)

700 participants with no apparent memory problems, which is anticipated to include 250 newly enrolled participants and 450 rollover participants from the prior ADNI3 study without apparent memory problems.
Strahlung: Neuraceq

Amyloid PET imaging with Florbetaben (Neuraceq) injection

Andere Namen:
  • Florbetaben
Strahlung: Amyvid

Amyloid PET imaging with Amyvid (Florbetapir) injection

Andere Namen:
  • Florbetapir
Strahlung: Tauvid

Tau PET imaging with Tauvid (Flortaucipir) injection

Andere Namen:
  • 18F-AV-1451
  • AV-1451
  • Flortaucipir
Strahlung: MK-6240

Tau PET imaging with MK-6240 injection

Andere Namen:
  • [18F]MK-6240
  • Florquinitau F-18
Strahlung: NAV4694

Amyloid PET imaging with NAV4694 injection

Andere Namen:
  • [18F]NAV4694
  • [18F]AZD4694
Strahlung: PI-2620

Tau PET imaging with PI-2620 injection

Andere Namen:
  • [18F]PI-2620
Mild Cognitive Impairment (MCI)

450 participants with mild cognitive impairment (MCI), which is anticipated to include 250 newly enrolled participants and 200 rollover participants from the prior ADNI3 study with MCI.
Strahlung: Neuraceq

Amyloid PET imaging with Florbetaben (Neuraceq) injection

Andere Namen:
  • Florbetaben
Strahlung: Amyvid

Amyloid PET imaging with Amyvid (Florbetapir) injection

Andere Namen:
  • Florbetapir
Strahlung: Tauvid

Tau PET imaging with Tauvid (Flortaucipir) injection

Andere Namen:
  • 18F-AV-1451
  • AV-1451
  • Flortaucipir
Strahlung: MK-6240

Tau PET imaging with MK-6240 injection

Andere Namen:
  • [18F]MK-6240
  • Florquinitau F-18
Strahlung: NAV4694

Amyloid PET imaging with NAV4694 injection

Andere Namen:
  • [18F]NAV4694
  • [18F]AZD4694
Strahlung: PI-2620

Tau PET imaging with PI-2620 injection

Andere Namen:
  • [18F]PI-2620
Dementia (DEM)

350 participants with mild dementia (DEM), which is anticipated to include 250 newly enrolled participants and 100 participants followed from the prior ADNI3 study with dementia.
Strahlung: Neuraceq

Amyloid PET imaging with Florbetaben (Neuraceq) injection

Andere Namen:
  • Florbetaben
Strahlung: Amyvid

Amyloid PET imaging with Amyvid (Florbetapir) injection

Andere Namen:
  • Florbetapir
Strahlung: Tauvid

Tau PET imaging with Tauvid (Flortaucipir) injection

Andere Namen:
  • 18F-AV-1451
  • AV-1451
  • Flortaucipir
Strahlung: MK-6240

Tau PET imaging with MK-6240 injection

Andere Namen:
  • [18F]MK-6240
  • Florquinitau F-18
Strahlung: NAV4694

Amyloid PET imaging with NAV4694 injection

Andere Namen:
  • [18F]NAV4694
  • [18F]AZD4694
Strahlung: PI-2620

Tau PET imaging with PI-2620 injection

Andere Namen:
  • [18F]PI-2620

Was misst die Studie?

Primäre Ergebnismessungen

Ergebnis Maßnahme
Maßnahmenbeschreibung
Zeitfenster
Rate of enrollment of Underrepresented Populations (URPs)
Zeitfenster: 5 years

The ADNI4 study aims to increased inclusion of underrepresented populations (URPs) to improve generalizability of results and advance our understanding of health disparities across URPs
5 years

Sekundäre Ergebnismessungen

Ergebnis Maßnahme
Maßnahmenbeschreibung
Zeitfenster
Veränderung der Amyloidablagerung, gemessen mit Florbetaben
Zeitfenster: CN- und MCI-Kohorten: Baseline/Anfang, Monat 24 und 48. DEM-Kohorten: Baseline/Anfang und Monat 24 und 36.
CN- und MCI-Kohorten: Baseline/Anfang, Monat 24 und 48. DEM-Kohorten: Baseline/Anfang und Monat 24 und 36.
Änderung der Amyloidablagerung, gemessen mit NAV4694
Zeitfenster: CN- und MCI-Kohorten: Baseline/Anfang, Monat 24 und 48. DEM-Kohorten: Baseline/Anfang und Monat 24 und 36.
CN- und MCI-Kohorten: Baseline/Anfang, Monat 24 und 48. DEM-Kohorten: Baseline/Anfang und Monat 24 und 36.
Veränderung der Amyloidablagerung, gemessen mit Florbetapir
Zeitfenster: CN- und MCI-Kohorten: Baseline/Anfang, Monat 24 und 48. DEM-Kohorten: Baseline/Anfang und Monat 24 und 36.
CN- und MCI-Kohorten: Baseline/Anfang, Monat 24 und 48. DEM-Kohorten: Baseline/Anfang und Monat 24 und 36.
Änderung der Tau-Ablagerung, gemessen mit Flortaucipir
Zeitfenster: CN- und MCI-Kohorten: Baseline/Anfang, Monat 24 und 48. DEM-Kohorten: Baseline/Anfang und Monat 24 und 36.
CN- und MCI-Kohorten: Baseline/Anfang, Monat 24 und 48. DEM-Kohorten: Baseline/Anfang und Monat 24 und 36.
Änderung der Tau-Ablagerung, gemessen mit MK-6240
Zeitfenster: CN- und MCI-Kohorten: Baseline/Anfang, Monat 24 und 48. DEM-Kohorten: Baseline/Anfang und Monat 24 und 36.
CN- und MCI-Kohorten: Baseline/Anfang, Monat 24 und 48. DEM-Kohorten: Baseline/Anfang und Monat 24 und 36.
Änderung der Tau-Ablagerung, gemessen mit PI-2620
Zeitfenster: CN- und MCI-Kohorten: Baseline/Anfang, Monat 24 und 48. DEM-Kohorten: Baseline/Anfang und Monat 24 und 36.
CN- und MCI-Kohorten: Baseline/Anfang, Monat 24 und 48. DEM-Kohorten: Baseline/Anfang und Monat 24 und 36.
Veränderung der Gehirnstruktur mittels Magnetresonanztomographie (MRT)
Zeitfenster: CN- und MCI-Kohorten: Screening/Erstaufnahme, Monat 24 und 48. DEM-Kohorten: Screening/Erstaufnahme und Monat 24 und 36.
CN- und MCI-Kohorten: Screening/Erstaufnahme, Monat 24 und 48. DEM-Kohorten: Screening/Erstaufnahme und Monat 24 und 36.
Rate of change in cognition as measured by the Category Fluency (Animals) Tests
Zeitfenster: CN Cohorts: Baseline/Initial, Months 24 and 48. MCI Cohorts: Baseline/Initial, Months 12, 24, 36 and 48. DEM Cohorts: Baseline/Initial, Months 12 and 24.

This is a measure of verbal fluency in which the participant is asked to generate examples from the semantic categories (animals) in successive one-minute trials
CN Cohorts: Baseline/Initial, Months 24 and 48. MCI Cohorts: Baseline/Initial, Months 12, 24, 36 and 48. DEM Cohorts: Baseline/Initial, Months 12 and 24.
Rate of change in cognition as measured by the Measurement of Everyday Cognition 12-item (12-Item ECog)
Zeitfenster: CN Cohorts: Baseline/Initial, Months 24 and 48. MCI Cohorts: Baseline/Initial, Months 12, 24, 36 and 48. DEM Cohorts: Baseline/Initial, Months 12 and 24.

Everyday Cognition (ECog) is a brief questionnaire assessing the participant's capability to perform normal everyday tasks, in comparison to activity levels at their own understanding of their prior baseline, using a 5-point scale. Previous research on this instrument indicates that ECog correlates well with established measures of functional status and global cognition but only weakly with age and education. ADNI4 will use the 12-item ECog with language updates from Farias et al. 2021 meant to improve generalizability across diverse groups.
CN Cohorts: Baseline/Initial, Months 24 and 48. MCI Cohorts: Baseline/Initial, Months 12, 24, 36 and 48. DEM Cohorts: Baseline/Initial, Months 12 and 24.
Rate of change in cognition as measured by the Logical Memory Test I and II (immediate and delayed paragraph recall)
Zeitfenster: CN Cohorts: Screening/Initial, Months 24 and 48. MCI Cohorts: Screening/Initial, Months 12, 24, 36 and 48. DEM Cohorts: Screening/Initial, Months 12 and 24.

We will use a modified episodic memory measure from the Wechsler Memory Scale- Revised (WMS-R) 24. In this modified version, free recall of one short story will be elicited immediately after it is read aloud to the participant and again after a thirty-minute delay
CN Cohorts: Screening/Initial, Months 24 and 48. MCI Cohorts: Screening/Initial, Months 12, 24, 36 and 48. DEM Cohorts: Screening/Initial, Months 12 and 24.
Rate of change in cognition as measured by the Montreal Cognitive Assessment (MoCA)
Zeitfenster: CN Cohorts: Baseline/Initial, Months 24 and 48. MCI Cohorts: Baseline/Initial, Months 12, 24, 36 and 48. DEM Cohorts: Baseline/Initial, Months 12 and 24.

The Montreal Cognitive Assessment test (MoCA) is, similar to the MMSE, a brief, 30- point cognitive assessment designed to detect participants at the MCI stage of cognitive dysfunction. This instrument has been shown to have adequate sensitivity and specificity in clinical settings to detect suspected MCI. The performance of the MoCA will be followed to determine its ability to differentiate among the three diagnostic groups in ADNI4
CN Cohorts: Baseline/Initial, Months 24 and 48. MCI Cohorts: Baseline/Initial, Months 12, 24, 36 and 48. DEM Cohorts: Baseline/Initial, Months 12 and 24.
Rate of change in cognition as measured by the Multilingual Naming Test (MINT)
Zeitfenster: CN Cohorts: Baseline/Initial, Months 24 and 48. MCI Cohorts: Baseline/Initial, Months 12, 24, 36 and 48. DEM Cohorts: Baseline/Initial, Months 12 and 24.

The Multilingual Naming Test (MINT) is a test of object picture naming designed to include items that are comparable across English, Spanish, Mandarin and Hebrew. It replaces the Boston Naming Test (BNT) in the Uniform Data Set of the NIA- funded Alzheimer's Disease Centers because the BNT contains items that are not of the same level of difficulty for Spanish- and English-speakers
CN Cohorts: Baseline/Initial, Months 24 and 48. MCI Cohorts: Baseline/Initial, Months 12, 24, 36 and 48. DEM Cohorts: Baseline/Initial, Months 12 and 24.
Rate of change in cognition as measured by the Perceived Stress (PSS)
Zeitfenster: CN Cohorts: Baseline/Initial, Months 24 and 48. MCI Cohorts: Baseline/Initial, Months 12, 24, 36 and 48. DEM Cohorts: Baseline/Initial, Months 12 and 24.

An important consideration in measuring cognition is current stress. Research suggests that current perceived stress can affect neurocognitive functioning (Lupien et al., 2009). Thus, measuring current stress in the present study is an important element of study procedures. The PSS measures current stress levels and stressful experiences in the last month. It asks about experiences such as feeling in control of one's life, feeling the ability to be productive, feeling overwhelmed, and being upset by unexpected events (Cohen, Kamarck, & Mermelstein, 1983). These items are rated on a Likert scale of 1-5, with 1 representing "Almost Always" and 5 representing "Almost Never." In scoring, the scale is reverse coded where appropriate, such that a low score is indicative of a lower level of perceived stress.
CN Cohorts: Baseline/Initial, Months 24 and 48. MCI Cohorts: Baseline/Initial, Months 12, 24, 36 and 48. DEM Cohorts: Baseline/Initial, Months 12 and 24.
Rate of change in cognition as measured by the Rey Auditory Verbal Learning Test (AVLT)
Zeitfenster: CN Cohorts: Baseline/Initial, Months 24 and 48. MCI Cohorts: Baseline/Initial, Months 12, 24, 36 and 48. DEM Cohorts: Baseline/Initial, Months 12 and 24.

The AVLT is a list-learning task, which assesses multiple cognitive parameters associated with learning and memory.
CN Cohorts: Baseline/Initial, Months 24 and 48. MCI Cohorts: Baseline/Initial, Months 12, 24, 36 and 48. DEM Cohorts: Baseline/Initial, Months 12 and 24.
Rate of change in cognition as measured by the Trail Making Test: A and B
Zeitfenster: CN Cohorts: Baseline/Initial, Months 24 and 48. MCI Cohorts: Baseline/Initial, Months 12, 24, 36 and 48. DEM Cohorts: Baseline/Initial, Months 12 and 24.

These two tests progress from a numerical connect-the-dots puzzle to a more challenging alternation between alpha- and numerical order. Although both Parts A and B depend on visuomotor and perceptual-scanning skills, Part B also requires considerable cognitive flexibility in shifting from number to letter sets under time pressure.
CN Cohorts: Baseline/Initial, Months 24 and 48. MCI Cohorts: Baseline/Initial, Months 12, 24, 36 and 48. DEM Cohorts: Baseline/Initial, Months 12 and 24.
Rate of change in cognition as measured by the Clinical Dementia Rating (CDR)
Zeitfenster: CN Cohorts: Screening/Initial, Months 24 and 48. MCI Cohorts: Screening/Initial, Months 12, 24, 36 and 48. DEM Cohorts: Screening/Initial, Months 12 and 24.

The Clinical Dementia Rating (CDR) describes five degrees of impairment in performance on each of 6 categories of cognitive functioning including memory, orientation, judgment and problem solving, community affairs, home and hobbies, and personal care. Impairment is scored on a scale in which none = 0, questionable = 0.5, mild = 1, moderate = 2 and severe = 3. A higher score indicates more impairment.
CN Cohorts: Screening/Initial, Months 24 and 48. MCI Cohorts: Screening/Initial, Months 12, 24, 36 and 48. DEM Cohorts: Screening/Initial, Months 12 and 24.
Rate of change in cognition as measured by the Activities of Daily Living (ADL) Functional Assessment Questionnaire (FAQ)
Zeitfenster: CN Cohorts: Baseline/Initial, Months 24 and 48. MCI Cohorts: Baseline/Initial, Months 12, 24, 36 and 48. DEM Cohorts: Baseline/Initial, Months 12 and 24.

Based on an interview with a caregiver or qualified partner, a participant is rated on his/her ability to carry out ten complex activities of daily living.
CN Cohorts: Baseline/Initial, Months 24 and 48. MCI Cohorts: Baseline/Initial, Months 12, 24, 36 and 48. DEM Cohorts: Baseline/Initial, Months 12 and 24.
Rate of change in cognition as measured by the Neuropsychiatric Inventory (NPI)
Zeitfenster: CN and MCI Cohorts: Baseline/Initial, Months 12, 24, 36 and 48. DEM Cohorts: Baseline/Initial, Months 12, 24 and 36.

The Neuropsychiatric Inventory (NPI) is a well-validated, reliable, multi-item instrument to assess psychopathology in AD based on an interview with a caregiver or qualified study partner. The NPI evaluates both the frequency and severity of 12 neuropsychiatric features, including: delusions, hallucinations, agitation/aggression, dysphoria, anxiety, euphoria, apathy, disinhibition, irritability/lability, aberrant motor behavior, sleep and appetite/eating disorders.

Frequency assessments range from 1 (occasionally, less than once per week) to 4 (very frequent, continuously present); severity from 1(mild), 2 (moderate) and 3 (severe) and distress from 0 (no distress) to 5 (very severe/extreme distress). For each behavioral domain, there are 4 scores: frequency, severity, domain score (frequency x severity) and caregiver distress. The total score is the sum of all domain scores. The distress score is not included in the total NPI score.
CN and MCI Cohorts: Baseline/Initial, Months 12, 24, 36 and 48. DEM Cohorts: Baseline/Initial, Months 12, 24 and 36.
Rate of change in cognition as measured by the Neuropsychiatric Inventory Q (NPI-Q)
Zeitfenster: CN and MCI Cohorts: Baseline/Initial, Months 12, 24, 36 and 48. DEM Cohorts: Baseline/Initial, Months 12, 24 and 36.

The Neuropsychiatric Inventory Q was designed as a version of the Neuropsychiatric Inventory (NPI) that could be administered more quickly and over the telephone. The NPI-Q measures the burden of 12 neuropsychiatric symptoms of dementia: delusions, hallucinations, agitation/aggression, depression/dysphoria, anxiety, elation/euphoria, apathy/indifference, disinhibition, irritability/lability, motor disturbance, nighttime behaviors, and appetite/eating.

Frequency assessments range from 1 (occasionally, less than once per week) to 4 (very frequent, continuously present); severity from 1(mild), 2 (moderate) and 3 (severe) and distress from 0 (no distress) to 5 (very severe/extreme distress). For each behavioral domain, there are 4 scores: frequency, severity, domain score (frequency x severity) and caregiver distress. The total score is the sum of all domain scores. The distress score is not included in the total NPI score.
CN and MCI Cohorts: Baseline/Initial, Months 12, 24, 36 and 48. DEM Cohorts: Baseline/Initial, Months 12, 24 and 36.
Rate of change in cognition as measured by the Geriatric Depression Scale (GDS) Short Form
Zeitfenster: CN Cohorts: Screening/Initial, Months 24 and 48. MCI Cohorts: Screening/Initial, Months 12, 24, 36 and 48. DEM Cohorts: Screening/Initial, Months 12 and 24.

The GDS Short Form is a self-report scale designed to screen for symptoms of depression in the elderly. The assessment is administered by clinic personnel to the study participant and consists of 15 questions that the participant is asked to answer yes or no on the basis of how they felt over the past week. Answers to 5 of the items are negatively oriented for depression (e.g., Do you feel full of energy?) and 10 positively oriented (e.g., Do you often feel helpless?). One point is given for each appropriate positive or negative answer indicative of a symptom of depression, for a possible total of 15 points. Although differing sensitivities and specificities have been obtained across studies, for clinical purposes a total score of 0-5 are considered likely to be normal and scores of 6-15 are considered to be more likely to be depressed.
CN Cohorts: Screening/Initial, Months 24 and 48. MCI Cohorts: Screening/Initial, Months 12, 24, 36 and 48. DEM Cohorts: Screening/Initial, Months 12 and 24.
Change in amyloid β-peptide (Aβ) 40 (Aβ40) in Cerebrospinal Fluid (CSF)
Zeitfenster: CN and MCI Cohorts: Baseline/Initial, Months 24 and 48. DEM Cohorts: Baseline/Initial and Month 24 and 36.

Cerebrospinal fluid (CSF) samples will be used to measure the levels of amyloid β-peptide (Aβ) 40. CSF Aβ40 is a key Alzheimer's disease (AD) biomarker that reflects pathological aggregation of amyloid in the brain.
CN and MCI Cohorts: Baseline/Initial, Months 24 and 48. DEM Cohorts: Baseline/Initial and Month 24 and 36.
Change in amyloid β-peptide (Aβ) 42 (Aβ42) in Cerebrospinal Fluid (CSF)
Zeitfenster: CN and MCI Cohorts: Baseline/Initial, Months 24 and 48. DEM Cohorts: Baseline/Initial and Month 24 and 36.

Cerebrospinal fluid (CSF) samples will be used to measure the levels of amyloid β-peptide (Aβ) 42. CSF Aβ42 is a key Alzheimer's disease (AD) biomarker that reflects pathological aggregation of amyloid in the brain.
CN and MCI Cohorts: Baseline/Initial, Months 24 and 48. DEM Cohorts: Baseline/Initial and Month 24 and 36.
Change in Cerebrospinal Fluid (CSF) Levels of Total Tau
Zeitfenster: CN and MCI Cohorts: Baseline/Initial, Months 24 and 48. DEM Cohorts: Baseline/Initial and Month 24 and 36.

Cerebrospinal fluid (CSF) samples will be used to measure the levels of total tau protein in the brain to assess impact on brain tau as a relevant Alzheimer's Disease (AD) biomarker.
CN and MCI Cohorts: Baseline/Initial, Months 24 and 48. DEM Cohorts: Baseline/Initial and Month 24 and 36.
Change in Cerebrospinal Fluid (CSF) Levels of Phospho-Tau 181
Zeitfenster: CN and MCI Cohorts: Baseline/Initial, Months 24 and 48. DEM Cohorts: Baseline/Initial and Month 24 and 36.

Cerebrospinal fluid (CSF) samples will be used to measure the levels of phospho-tau 181 protein in the brain to assess impact on brain tau as a relevant Alzheimer's Disease (AD) biomarker.
CN and MCI Cohorts: Baseline/Initial, Months 24 and 48. DEM Cohorts: Baseline/Initial and Month 24 and 36.

Mitarbeiter und Ermittler

Hier finden Sie Personen und Organisationen, die an dieser Studie beteiligt sind.

Sponsor

University of Southern California

Mitarbeiter

National Institute on Aging (NIA)
Northern California Institute of Research and Education
Alzheimer's Therapeutic Research Institute

Ermittler

  • Hauptermittler: Ronald Petersen, MD, PHD, Mayo Clinic
  • Hauptermittler: Paul Aisen, MD, USC Alzheimer's Therapeutic Research Institute (ATRI)
  • Studienleiter: Michael Weiner, MD, University of California, San Francisco

Studienaufzeichnungsdaten

Diese Daten verfolgen den Fortschritt der Übermittlung von Studienaufzeichnungen und zusammenfassenden Ergebnissen an ClinicalTrials.gov. Studienaufzeichnungen und gemeldete Ergebnisse werden von der National Library of Medicine (NLM) überprüft, um sicherzustellen, dass sie bestimmten Qualitätskontrollstandards entsprechen, bevor sie auf der öffentlichen Website veröffentlicht werden.

Haupttermine studieren

Studienbeginn (Tatsächlich)

9. Juni 2023

Primärer Abschluss (Geschätzt)

31. Juli 2027

Studienabschluss (Geschätzt)

31. Juli 2027

Studienanmeldedaten

Zuerst eingereicht

2. November 2022

Zuerst eingereicht, das die QC-Kriterien erfüllt hat

8. November 2022

Zuerst gepostet (Tatsächlich)

15. November 2022

Studienaufzeichnungsaktualisierungen

Letztes Update gepostet (Tatsächlich)

29. September 2026

Letztes eingereichtes Update, das die QC-Kriterien erfüllt

23. September 2026

Zuletzt verifiziert

1. August 2026

Mehr Informationen

Begriffe im Zusammenhang mit dieser Studie

Schlüsselwörter

Zusätzliche relevante MeSH-Bedingungen

Andere Studien-ID-Nummern

  • ATRI-011
  • U19AG024904 (US NIH Stipendium/Vertrag)

Plan für individuelle Teilnehmerdaten (IPD)

Planen Sie, individuelle Teilnehmerdaten (IPD) zu teilen?

JA

Art der unterstützenden IPD-Freigabeinformationen

  • STUDIENPROTOKOLL
  • SAFT
  • ICF

Arzneimittel- und Geräteinformationen, Studienunterlagen

Studiert ein von der US-amerikanischen FDA reguliertes Arzneimittelprodukt

Nein

Studiert ein von der US-amerikanischen FDA reguliertes Geräteprodukt

Nein

Diese Informationen wurden ohne Änderungen direkt von der Website clinicaltrials.gov abgerufen. Wenn Sie Ihre Studiendaten ändern, entfernen oder aktualisieren möchten, wenden Sie sich bitte an register@clinicaltrials.gov. Sobald eine Änderung auf clinicaltrials.gov implementiert wird, wird diese automatisch auch auf unserer Website aktualisiert .

Abonnieren